These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 33654056)

  • 1. Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.
    MahmoudianDehkordi S; Ahmed AT; Bhattacharyya S; Han X; Baillie RA; Arnold M; Skime MK; John-Williams LS; Moseley MA; Thompson JW; Louie G; Riva-Posse P; Craighead WE; McDonald W; Krishnan R; Rush AJ; Frye MA; Dunlop BW; Weinshilboum RM; Kaddurah-Daouk R;
    Transl Psychiatry; 2021 Mar; 11(1):153. PubMed ID: 33654056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.
    Sarris J; Papakostas GI; Vitolo O; Fava M; Mischoulon D
    J Affect Disord; 2014 Aug; 164():76-81. PubMed ID: 24856557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.
    Ahmed AT; MahmoudianDehkordi S; Bhattacharyya S; Arnold M; Liu D; Neavin D; Moseley MA; Thompson JW; Williams LSJ; Louie G; Skime MK; Wang L; Riva-Posse P; McDonald WM; Bobo WV; Craighead WE; Krishnan R; Weinshilboum RM; Dunlop BW; Millington DS; Rush AJ; Frye MA; Kaddurah-Daouk R;
    J Affect Disord; 2020 Mar; 264():90-97. PubMed ID: 32056779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data.
    Bobo WV; Angleró GC; Jenkins G; Hall-Flavin DK; Weinshilboum R; Biernacka JM
    Hum Psychopharmacol; 2016 May; 31(3):185-92. PubMed ID: 26999588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.
    Bhattacharyya S; Ahmed AT; Arnold M; Liu D; Luo C; Zhu H; Mahmoudiandehkordi S; Neavin D; Louie G; Dunlop BW; Frye MA; Wang L; Weinshilboum RM; Krishnan RR; Rush AJ; Kaddurah-Daouk R
    Transl Psychiatry; 2019 Jul; 9(1):173. PubMed ID: 31273200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder.
    Weber S; Frokjaer VG; Armand S; Nielsen JH; Knudsen GM; Joergensen MB; Stenbaek DS; Giraldi A
    J Sex Med; 2023 Feb; 20(2):161-169. PubMed ID: 36763929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.
    Mrazek DA; Biernacka JM; McAlpine DE; Benitez J; Karpyak VM; Williams MD; Hall-Flavin DK; Netzel PJ; Passov V; Rohland BM; Shinozaki G; Hoberg AA; Snyder KA; Drews MS; Skime MK; Sagen JA; Schaid DJ; Weinshilboum R; Katzelnick DJ
    J Clin Psychopharmacol; 2014 Jun; 34(3):313-7. PubMed ID: 24743713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escitalopram: a review of its use in the management of major depressive disorder in adults.
    Garnock-Jones KP; McCormack PL
    CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
    Kennedy SH; Andersen HF; Thase ME
    Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
    Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
    Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
    Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV
    Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study.
    Lin YT; Lu TS; Hansen RA; Wang CC
    Clin Ther; 2019 Jun; 41(6):1128-1138.e8. PubMed ID: 31178037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.